Blog

The emergence of new drugs and therapies for early stage Alzheimer’s disease (AD), known as mild cognitive impairment (MCI) or mild dementia, has intensified the challenge of identifying the most appropriate, cost-effective treatment for (AD). The risk-benefit of these new disease modifying agents has raised urgency for accurate tests to verify an AD diagnosis earlier in the disease …

An estimated 5.8 million Americans age 65 and older live with Alzheimer’s disease (AD), a progressive disease that destroys memory and other important mental functions, with projections showing that by 2050 that number will reach 12.7 million.  AD tends to progress slowly in three general stages: early or mild cognitive impairment (MCI), moderate and severe. Because AD affects people in different ways, each person may experience …

An early diagnosis of Alzheimer’s Disease (AD) can help determine if the symptoms a patient is experiencing are truly due to AD or some other conditions that may be treatable. Unfortunately, when it comes to diagnostic tests for AD, considerable confusion has prevailed in the marketplace, often without clarity of the clinical importance of what …

Knowing the Difference: Alzheimer’s Disease vs. Other Types of Dementia  Alzheimer’s disease (AD) is the most common type of dementia, but there are many other kinds of dementia, including Lewy body dementia, Huntington’s disease and non-Alzheimer’s dementias. Not a normal part of aging, dementia is caused by damage to brain cells that affects an individual’s ability …

DISCERN™ Receives First-in-Category PLA Codes SYNAPS Dx (SDx) is pleased to announce that DISCERN™ is the first AD test to earn Proprietary Laboratory Analyses (PLA) Codes 206U and 207U.  DISCERN™ is the first autopsy-validated, highly accurate, minimally invasive test for the definitive diagnosis of AD versus other forms of non-AD dementias and those with AD and other degenerative …

SYNAPS Dx Completes $10 Million Series A Investment Accelerates Commercialization of DISCERN™: First Minimally Invasive Test for Accurate Diagnosis of Alzheimer’s Disease There are approximately 500,000 new cases of dementia each year in the United States, with about 2 million patients in years 0-3 of the disease at any given time. With the emergence of new drugs …

SYNAPS Dx Joins Maryland Tech Council A new independent study finds that Maryland has built one of the nation’s strongest life sciences industries, which directly employs more than 54,000 workers. A division of MTC, Maryland Life Sciences, recently commissioned a report from the globally recognized Milken Institute that also identifies new opportunities for the public and private sectors to …

ROCKVILLE, Md.–(BUSINESS WIRE)–SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of diagnostics for neurodegenerative disorders and conditions, including Alzheimer’s Disease (AD), announces that DISCERN™, the first autopsy-validated, highly accurate, minimally invasive test for the definitive diagnosis of AD versus other forms of non-AD dementias and those with AD and other degenerative …

ROCKVILLE, Md. – (BUSINESS WIRE) –SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of diagnostics for neurodegenerative disorders and conditions, including Alzheimer’s Disease (AD), announces the close of its Series A $10 million investment, including private equity, individual and family funds, and corporate investors. Proceeds will be used to scale-up …